Major depressive disorder (MDD) is among the most common and disabling psychiatric conditions encountered in general medical and psychiatric practice, and a leading global contributor to years lived with disability. DSM-5-TR places MDD within the depressive disorders chapter and defines it by recurrent or single major depressive episodes characterized by at least two weeks of depressed mood or anhedonia with associated neurovegetative, cognitive, and psychomotor changes. ICD-11 retains a comparable construct under chapter 06, with mild, moderate, and severe gradations and a separate code for recurrent depressive disorder. Two clinical takeaways anchor the topic: depression is a heterogeneous syndrome whose treatment must be matched to severity, recurrence, and comorbidity, and suicide risk assessment is a non-delegable part of every depressive episode encounter. The bottom line for the clinician is that early recognition, structured measurement, and stepped care with first-line SSRIs or evidence-based psychotherapy produce remission in roughly half of treated patients on the first attempt, with sequential strategies needed for the rest.

MDD is one of the most prevalent psychiatric disorders worldwide, with a strong female predominance and substantial psychiatric and medical comorbidity. The disorder is a leading global cause of disability and a major driver of suicide mortality.^1-2

Prevalence and demographics

• Lifetime prevalence in U.S. adults is approximately 20.6%, with 12-month prevalence near 10.4% in the National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC-III).³
• The female-to-male ratio is approximately 2:1, emerging in adolescence and persisting across adulthood.^1,4
• Median age of onset is in the mid-20s, but first episodes occur across the lifespan, including childhood and late life.^1,4
• Global point prevalence rose during the COVID-19 pandemic, with WHO and Global Burden of Disease estimates reporting a roughly 25-28% increase in major depression in 2020.⁵

Comorbidity

• Anxiety disorders co-occur with MDD in roughly 50-60% of cases over the lifetime.³
• Substance use disorders, particularly alcohol use disorder, co-occur in approximately 25-40% of patients with MDD.³
• Chronic medical illness (cardiovascular disease, diabetes, chronic pain, stroke) substantially increases MDD risk and worsens both psychiatric and medical outcomes.⁶
• Lifetime suicide attempt rates are elevated severalfold in MDD, and depression is identified retrospectively in a majority of completed suicides.⁷

Risk factors

• Female sex, family history of mood disorder, childhood adversity, recent psychosocial stressors, postpartum status, chronic medical illness, and lower socioeconomic status are consistent risk markers.^1,6
• Heritability is approximately 35-40% based on twin studies, lower than for bipolar disorder or schizophrenia.⁸

No single biological lesion explains MDD; the disorder is best understood as a final common pathway of interacting monoaminergic, neuroplastic, neuroendocrine, inflammatory, and circuit-level abnormalities shaped by genetic vulnerability and environmental stress.^9-10

Neurotransmitter systems

• The classical monoamine hypothesis posits deficient serotonergic, noradrenergic, and dopaminergic transmission, supported by the antidepressant effects of agents that increase synaptic monoamines.⁹
• The monoamine framework is incomplete: tryptophan depletion does not reliably induce depression in healthy controls, and antidepressant clinical response lags behind acute monoamine elevation by weeks, implicating downstream plasticity changes.^9-10
• Glutamatergic dysregulation, particularly NMDA receptor signaling and synaptic plasticity in cortico-limbic circuits, is supported by the rapid antidepressant effect of subanesthetic ketamine and esketamine.¹¹

Neurocircuits and imaging

• Functional imaging shows hyperactivity of the subgenual anterior cingulate cortex (Brodmann area 25) and amygdala, with reduced dorsolateral prefrontal engagement during cognitive tasks.¹²
• Aberrant connectivity within the default mode network is associated with rumination and self-referential processing in depressed patients.¹²
• Structural MRI studies report modest hippocampal volume reductions, particularly with longer illness duration and untreated episodes.¹³

Neuroendocrine and inflammatory factors

• HPA axis hyperactivity, with elevated cortisol and impaired dexamethasone suppression, is the most replicated neuroendocrine finding in melancholic and severe depression, though not specific enough for clinical use.¹⁴
• Elevated peripheral inflammatory markers (CRP, IL-6, TNF-alpha) are reproducibly associated with depression, particularly in patients with comorbid medical illness or treatment resistance.¹⁵

Genetics

• Heritability is approximately 35-40%; large GWAS meta-analyses have identified more than 100 genome-wide significant loci, each of small effect, with substantial polygenic overlap with anxiety and neuroticism.^8,16
• No single gene variant is clinically actionable for MDD diagnosis or treatment selection at present.¹⁶

Environmental contributors

• Childhood maltreatment, recent adverse life events, chronic interpersonal stress, low social support, and bereavement are robust precipitants and prognostic factors.^6,17
• Postpartum hormonal shifts, hypothyroidism, corticosteroid exposure, and interferon therapy are well-documented biological precipitants.^1,6

DSM-5-TR diagnoses MDD when a patient meets criteria for at least one major depressive episode in the absence of a history of mania or hypomania. The diagnosis is syndromal and clinical; no biomarker is required or sufficient.¹

Major depressive episode

• At least five of nine symptoms present during the same two-week period and representing a change from baseline, with at least one being depressed mood or loss of interest or pleasure.¹
  • Depressed mood most of the day, nearly every day.¹
  • Markedly diminished interest or pleasure in nearly all activities.¹
  • Significant weight change or appetite disturbance.¹
  • Insomnia or hypersomnia nearly every day.¹
  • Psychomotor agitation or retardation observable by others.¹
  • Fatigue or loss of energy.¹
  • Feelings of worthlessness or excessive or inappropriate guilt.¹
  • Diminished concentration or indecisiveness.¹
  • Recurrent thoughts of death, suicidal ideation, plan, or attempt.¹
• Symptoms cause clinically significant distress or functional impairment.¹
• Symptoms are not attributable to a substance or another medical condition.¹
• The episode is not better explained by a schizophrenia spectrum or other psychotic disorder, and there has never been a manic or hypomanic episode unrelated to a substance or medical condition.¹

Severity, course, and specifiers

• Severity is coded as mild, moderate, or severe based on symptom count, intensity, and functional impairment.¹
• Course modifiers include single episode versus recurrent, in partial remission, in full remission, and unspecified.¹
• DSM-5-TR specifiers include with anxious distress, mixed features, melancholic features, atypical features, mood-congruent or mood-incongruent psychotic features, catatonia, peripartum onset, and seasonal pattern.¹
• The DSM-IV bereavement exclusion was removed in DSM-5; grief and MDD can co-occur and a depressive episode can be diagnosed within the first two months after a loss when criteria are met.¹

Depressive episodes vary widely in symptom emphasis and trajectory; recognizing prototypical and atypical patterns drives both diagnosis and treatment selection.^1,4

Symptom clusters

• Affective: depressed, empty, or irritable mood; tearfulness; diminished reactivity; feelings of hopelessness.^1,4
• Cognitive: rumination, worthlessness, guilt, indecisiveness, slowed thinking, impaired attention and working memory.¹⁹
• Neurovegetative: insomnia (typically early morning awakening) or hypersomnia, appetite or weight change, fatigue, decreased libido.^1,4
• Psychomotor: psychomotor retardation or, less commonly, agitation, often visible at the bedside in severe episodes.^1,4
• Somatic: nonspecific pain, gastrointestinal symptoms, and headache, particularly in primary care presentations.²⁰

Specifier-defined presentations

• Melancholic features: pervasive anhedonia, mood worse in the morning, early morning awakening, marked psychomotor change, significant weight loss, and excessive guilt; classically responsive to ECT and TCAs.^1,21
• Atypical features: mood reactivity preserved plus leaden paralysis, rejection sensitivity, hyperphagia, or hypersomnia; historically associated with MAOI responsiveness.^1,21
• Anxious distress: tense, restless, or worried; common and prognostically worse, including for suicide.¹
• Mixed features: subthreshold manic/hypomanic symptoms during a depressive episode; raises bipolar suspicion and complicates antidepressant choice.^1,22
• Psychotic features: mood-congruent or mood-incongruent delusions or hallucinations; requires combination antipsychotic plus antidepressant or ECT.^1,23
• Peripartum onset: episode begins during pregnancy or within four weeks postpartum; warrants psychotic-symptom and infanticide risk screening when severe.¹
• Seasonal pattern: temporally linked recurrence, classically fall-winter onset; bright light therapy is supported.^1,24
• Catatonia: stupor, mutism, posturing, waxy flexibility; responds to benzodiazepines and ECT.^1,25

Course features

• Untreated episodes typically last 6-12 months, with shorter duration when treated; residual symptoms after recovery are common and predict relapse.⁴
• Recurrence risk after a single episode is approximately 50%, rising to 70% after a second and 90% after a third episode.⁴
• Red flags for bipolarity in a depressed patient include early age of onset, postpartum onset, recurrent episodes with rapid recovery, family history of bipolar disorder, antidepressant-induced activation, and psychotic features.²²

Depressed mood is the final common pathway of many psychiatric, medical, and substance-related conditions. The most consequential error is missing bipolar disorder before initiating antidepressant monotherapy.^1,22

Psychiatric differentials

• Bipolar I or II depression: identical cross-sectional presentation; requires lifetime mood history.^1,22
• Persistent depressive disorder (dysthymia): chronic depressed mood for at least two years in adults with fewer acute symptoms; can co-occur with episodic MDD ("double depression").¹
• Adjustment disorder with depressed mood: subthreshold response to identifiable stressor within three months.¹
• Premenstrual dysphoric disorder: symptoms confined to the luteal phase with follicular remission.¹
• Disruptive mood dysregulation disorder: pediatric persistent irritability with severe outbursts; diagnosed before age 18 with onset before age 10.¹
• Bereavement and prolonged grief disorder: yearning and preoccupation with the deceased dominate; MDD is diagnosed when full criteria are met independent of grief context.¹
• Anxiety disorders, PTSD, and OCD: frequently comorbid; the diagnosis is added rather than substituted when full MDD criteria are met.³
• Schizoaffective disorder and depression with psychotic features: differentiated by whether psychosis occurs in the absence of a mood episode.¹
• Substance/medication-induced depressive disorder: temporally tied to intoxication, withdrawal, or medication exposure (alcohol, sedatives, stimulant withdrawal, corticosteroids, interferon, isotretinoin).¹

Medical mimics

• Endocrine: hypothyroidism, hyperthyroidism, Cushing syndrome, Addison disease, hyperparathyroidism.⁶
• Neurologic: Parkinson disease, stroke (particularly left frontal), multiple sclerosis, dementia, traumatic brain injury, epilepsy.⁶
• Infectious and inflammatory: HIV, neurosyphilis, hepatitis C, autoimmune encephalitis, systemic lupus erythematosus.⁶
• Oncologic and metabolic: pancreatic cancer, vitamin B12 and folate deficiency, anemia, electrolyte disturbance, obstructive sleep apnea.⁶
• Pharmacologic: corticosteroids, interferon-alpha, beta-blockers (less robust association than historically taught), varenicline (FDA boxed warning removed in 2016 after EAGLES), levetiracetam, isotretinoin, hormonal contraceptives in vulnerable patients.^6,26

Diagnosis rests on a structured clinical interview supplemented by collateral information, validated rating scales, and targeted medical workup to exclude mimics.^1-2

History and interview

• Characterize the current episode: onset, duration, symptom inventory, severity, functional impact, prior episodes, and treatment history.²
• Screen explicitly for past mania or hypomania, psychotic symptoms, mixed features, and seasonal pattern.^1,22
• Obtain substance use, medication, and medical history; review caregiving and occupational stressors and recent losses.²
• Document family history of mood, psychotic, and substance use disorders, and any suicide history in first-degree relatives.²

Suicide risk assessment

• Ask directly about ideation, intent, plan, access to means, prior attempts, recent loss or humiliation, hopelessness, and command hallucinations.^7,27
• Use a structured instrument such as the Columbia Suicide Severity Rating Scale (C-SSRS) to anchor the assessment, recognizing that no scale predicts suicide reliably.²⁷

Rating scales

• PHQ-9: nine-item self-report aligned to DSM symptoms; cutoffs 5/10/15/20 correspond to mild/moderate/moderately severe/severe depression and item 9 screens suicidal ideation.²⁸
• Hamilton Depression Rating Scale (HAM-D, 17- or 21-item): clinician-administered, the historical research benchmark.²⁹
• Montgomery-Asberg Depression Rating Scale (MADRS): clinician-administered, more sensitive to change than HAM-D in many trials.³⁰
• Quick Inventory of Depressive Symptomatology (QIDS-SR-16): self-report used in STAR*D and routine measurement-based care.³¹
• Edinburgh Postnatal Depression Scale (EPDS): perinatal-specific, validated in pregnancy and postpartum.³²
• Geriatric Depression Scale (GDS): de-emphasizes somatic items in older adults.³³

Physical exam and laboratory workup

• Targeted physical and neurological exam; vital signs and weight at baseline.²
• Routine baseline labs: CBC, comprehensive metabolic panel, TSH, vitamin B12, and pregnancy test in patients of reproductive potential before initiating pharmacotherapy.²
• Consider HIV, RPR, and folate when clinical suspicion exists; vitamin D in selected patients.²
• Routine neuroimaging is not indicated; reserve MRI for atypical features (focal neurologic findings, late onset, rapid cognitive decline, treatment resistance with neurologic suspicion).²
• Avoid ordering EEG, genetic testing for treatment selection, or pharmacogenomic panels as routine workup; current evidence does not support changing first-line management on the basis of these results.³⁴

Treatment is matched to severity, prior response, comorbidity, and patient preference. Mild episodes are reasonably treated with evidence-based psychotherapy alone; moderate-to-severe episodes warrant pharmacotherapy, often combined with psychotherapy, and severe or psychotic episodes require combination treatment or ECT.^2,36-37

Pharmacotherapy

• First-line agents are SSRIs and SNRIs across major guidelines (APA, NICE, CANMAT), based on a favorable balance of efficacy, tolerability, and safety in overdose compared with TCAs and MAOIs.^2,36-37
  • SSRIs: sertraline, escitalopram, citalopram, fluoxetine, paroxetine, fluvoxamine.³⁷
  • SNRIs: venlafaxine, desvenlafaxine, duloxetine, levomilnacipran.³⁷
  • Atypical/other first-line: bupropion (norepinephrine-dopamine reuptake inhibitor; favorable for fatigue and sexual side-effect profile, contraindicated in seizure or eating disorders) and mirtazapine (alpha-2 antagonist with 5-HT2 and H1 effects; useful for insomnia and weight loss).³⁷
• A 2018 network meta-analysis of 522 trials (Cipriani et al.) found all 21 antidepressants studied more efficacious than placebo, with sertraline, escitalopram, mirtazapine, and vortioxetine combining favorable efficacy and acceptability among newer agents.³⁸
• Allow 4-6 weeks at therapeutic dose before declaring nonresponse; partial responders may benefit from 2-4 additional weeks.^2,36
• After remission, continue the effective antidepressant at the acute-phase dose for 6-12 months for a single episode, and indefinitely for patients with three or more lifetime episodes or chronic course.^2,36

Treatment-resistant depression

• Defined commonly as failure of at least two adequate antidepressant trials of different classes at adequate dose and duration in the current episode.³⁹
• STAR*D demonstrated cumulative remission of approximately 67% across four sequenced steps, with diminishing returns and rising relapse rates at each step; most patients required more than one trial.⁴⁰
• Augmentation strategies with the strongest evidence include atypical antipsychotics (aripiprazole, brexpiprazole, quetiapine XR, olanzapine-fluoxetine combination, cariprazine), lithium, and triiodothyronine (T3).^39,41
• Switching within or across classes is reasonable after first failure; combining an SSRI/SNRI with bupropion or mirtazapine is supported by limited evidence and used in practice.^39-40
• Esketamine intranasal spray (FDA approved 2019) is indicated for treatment-resistant depression in conjunction with an oral antidepressant, with a REMS program for sedation, dissociation, and abuse potential.⁴²
• Racemic intravenous ketamine produces rapid but transient antidepressant effects within hours; it is widely used off-label, with the strongest evidence for short-term reduction of suicidal ideation.^11,43

Psychotherapy

• Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) have the strongest evidence for acute MDD, comparable to antidepressants for mild-to-moderate episodes.^44-45
• Behavioral activation is non-inferior to full CBT in head-to-head trials and is the recommended psychotherapy in NICE stepped-care for mild depression.⁴⁶
• Mindfulness-based cognitive therapy (MBCT) reduces relapse risk in patients with three or more prior episodes and is recommended for relapse prevention in NICE.⁴⁷
• Combination of antidepressant plus psychotherapy is more effective than either alone for moderate-to-severe MDD and chronic depression.^44,48

Neuromodulation

• Electroconvulsive therapy (ECT) is the most effective treatment for severe, psychotic, catatonic, or treatment-resistant depression, with response rates of 60-80% in clinical samples; cognitive side effects (transient anterograde and retrograde amnesia) are the principal harm.^23,49
• Repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex is FDA-cleared for MDD after failure of one antidepressant; effect size is modest, and accelerated and theta-burst protocols are increasingly used.⁵⁰
• Vagus nerve stimulation is FDA-approved for chronic or recurrent treatment-resistant depression but is rarely first-line because of invasiveness and modest acute effect.⁵¹
• Deep brain stimulation remains investigational for MDD.⁵²

Adjunctive

• Bright light therapy (10,000 lux for 30 minutes in the morning) has strong evidence for seasonal depression and moderate evidence for non-seasonal MDD.²⁴
• Aerobic exercise as an adjunct produces modest antidepressant effects, with the strongest evidence in mild-to-moderate depression.⁵³
• Sleep deprivation produces rapid but transient improvement and is largely a research tool.⁵⁴
• Omega-3 fatty acids (EPA-predominant) and S-adenosyl-L-methionine (SAMe) have low-to-moderate evidence as adjuncts.³⁷
• Address comorbid substance use, sleep apnea, hypothyroidism, and chronic pain in parallel; failure to do so accounts for many "treatment-resistant" cases.^2,6

All antidepressants carry adverse-effect burdens that drive nonadherence and discontinuation. The evidence base is also weighted toward short-term efficacy in narrow trial populations, limiting generalizability to the multimorbid patients seen in clinic.^38,55

Common adverse effects

• SSRIs and SNRIs: GI upset, headache, insomnia or sedation, sexual dysfunction (25-70%, often persistent), increased sweating, and weight gain on long-term exposure.³⁷
• Bupropion: insomnia, agitation, headache, dry mouth, and dose-dependent seizure risk.³⁷
• Mirtazapine: sedation, increased appetite, and weight gain.³⁷
• TCAs: anticholinergic effects, orthostatic hypotension, weight gain, sedation, and cardiac conduction prolongation.³⁷
• MAOIs: orthostatic hypotension, weight gain, sexual dysfunction, and dietary or drug interactions.³⁷

Serious or rare adverse effects

• Hyponatremia from SIADH, particularly in older adults on SSRIs or SNRIs.⁵⁶
• Increased upper GI bleeding risk with SSRIs, additive with NSAIDs and anticoagulants.⁵⁷
• Serotonin syndrome with serotonergic combinations (SSRI plus MAOI, linezolid, tramadol, triptans, MDMA).⁵⁸
• QTc prolongation with citalopram doses above 40 mg (20 mg in patients over 60); FDA dose limits issued in 2011-2012.⁵⁹
• Hypertensive crisis with MAOIs and tyramine-rich foods or sympathomimetics.³⁷
• TCA cardiotoxicity in overdose (sodium-channel blockade, QRS widening).³⁷
• Suicidality: FDA boxed warning for increased suicidal ideation and behavior in patients under 25 in the first weeks of antidepressant treatment.⁶⁰

Monitoring and discontinuation considerations

• Reassess response and adverse effects every 1-2 weeks during titration and at least every 4 weeks until remission, then every 1-3 months in maintenance.^2,35
• Monitor sodium in older adults at baseline and 2-4 weeks after starting an SSRI/SNRI.⁵⁶
• Reassess long-term need at recurrence-defined intervals; do not assume indefinite treatment is needed for a single episode.²

Limitations of the evidence base

• Most RCTs use 8-12 week endpoints with selected populations, limiting inference about long-term outcomes.⁵⁵
• Publication bias has historically inflated apparent effect sizes; the Turner 2008 NEJM analysis showed unfavorable trials were less often published.⁶²
• Pediatric and geriatric data are thinner; older adults are underrepresented and head-to-head pediatric RCTs remain limited.⁶³
• Few trials directly compare sequential strategies; most evidence after first-line failure rests on STAR*D and smaller augmentation trials.⁴⁰

Modifications to first-line management are required across the lifespan and in medical comorbidity. The principles are conservative dosing, attention to drug interactions, and integration with non-psychiatric care.^2,37

Pediatric and adolescent

• Fluoxetine and escitalopram are FDA-approved for adolescent MDD; fluoxetine has the strongest evidence and is approved from age 8.⁶⁴
• The TADS trial showed combined fluoxetine plus CBT outperformed either alone in adolescents with moderate-to-severe MDD; CBT alone was not superior to placebo at 12 weeks.⁶⁵
• TORDIA demonstrated that switching to a different SSRI plus CBT was superior to medication switch alone in SSRI-resistant adolescent depression.⁶⁶
• The FDA boxed warning for increased suicidal ideation and behavior in patients under 25 mandates close monitoring during initial treatment.⁶⁰

Geriatric

• Start low, go slow; SSRIs and SNRIs are preferred over TCAs because of falls, anticholinergic burden, and cardiac risk.⁶⁷
• Sertraline, escitalopram, and mirtazapine are common first-line choices in older adults; paroxetine is generally avoided due to anticholinergic and discontinuation effects.⁶⁷
• Late-life depression with executive dysfunction ("vascular depression") shows poorer SSRI response and may benefit from problem-solving therapy or ECT.⁶⁸
• Monitor sodium, falls, drug interactions, and renal function regularly.⁶⁷

Perinatal

• Untreated antenatal depression is itself associated with adverse maternal and neonatal outcomes; treatment decisions weigh treatment risks against the risks of untreated illness.⁶⁹
• Sertraline is a commonly preferred SSRI in pregnancy and lactation due to favorable transfer profile, though most SSRIs are reasonable options.^69-70
• Paroxetine has a small absolute increase in cardiac malformation signal in some studies and is generally avoided in early pregnancy when alternatives exist.⁷¹
• Late third-trimester SSRI exposure can cause transient neonatal adaptation syndrome and a small absolute increase in persistent pulmonary hypertension of the newborn.⁷²
• Brexanolone and zuranolone are FDA-approved for postpartum depression; zuranolone (oral, 14-day course) was approved in 2023 with rapid onset.^73-74

Comorbid medical illness

• Post-stroke depression: SSRIs are first-line; treat actively, as untreated depression worsens rehabilitation outcomes.⁷⁵
• Cardiovascular disease: SSRIs (sertraline preferred) are safer than TCAs post-MI; SADHART trial supported sertraline safety.⁷⁶
• Cancer: depression is undertreated in oncologic populations; SSRIs and mirtazapine are commonly used; avoid paroxetine and fluoxetine with tamoxifen due to CYP2D6 inhibition.⁷⁷
• Parkinson disease: SSRIs and SNRIs are reasonable; pramipexole and ECT have specific roles in selected patients.⁷⁸
• Chronic pain: duloxetine and TCAs are particularly useful when pain is comorbid.⁷⁹

Comorbid substance use

• Treat MDD and substance use disorder concurrently; substance-induced depressive disorder may remit with sustained abstinence.⁸⁰
• Alcohol use disorder: SSRIs are first-line; consider naltrexone or acamprosate for the alcohol component.⁸⁰

Cultural considerations

• Somatic presentations of depression (fatigue, pain, GI symptoms) are more common in some cultural contexts and primary care settings; the diagnosis should not require Western affective vocabulary.²⁰
• Stigma, language, and idioms of distress shape help-seeking and adherence; ask in the patient's framework.⁸¹

MDD is typically episodic and recurrent, with substantial heterogeneity. Functional recovery often lags symptomatic remission, and residual symptoms are the strongest predictor of relapse.^4,82

Course parameters

• Treated episodes typically remit within 3-6 months; untreated episodes last 6-12 months on average.⁴
• Across an average lifetime, patients with MDD experience 4-7 episodes; 10-30% develop a chronic course.⁴
• Recurrence risk after one, two, and three episodes is approximately 50%, 70%, and 90% respectively.⁴

Response and remission

• STAR*D demonstrated step-1 (citalopram) remission of approximately 28-33% on QIDS-SR and HAM-D criteria, with cumulative remission near 67% across four steps.⁴⁰
• Response (>=50% symptom reduction) typically precedes remission; residual symptoms after "response" predict relapse.⁸²
• Full functional recovery (occupational, interpersonal, cognitive) lags symptomatic remission by months.⁸²

Mortality

• MDD is associated with elevated all-cause mortality, mediated by suicide, cardiovascular disease, and metabolic comorbidity.⁸³
• Lifetime suicide risk in MDD has historically been quoted at 15%, but more rigorous analyses estimate 3-7% in mixed samples and higher in inpatient populations.^7,84

Depressed patients can deteriorate rapidly. Triage decisions hinge on suicide risk, ability to maintain safety, psychotic features, severe self-neglect, and access to outpatient follow-up.^2,7

Hospitalization criteria

• Active suicidal intent, plan, or recent attempt without a credible safety plan.^2,7
• Severe self-neglect, inability to perform basic self-care, or catatonia.²
• Psychotic features endangering the patient or others.²³
• Failure of intensive outpatient treatment with worsening severity.²

Suicide risk markers

• Static factors: prior attempts (the strongest predictor), male sex, older age, family history of suicide, comorbid substance use, chronic pain, and access to firearms.⁷
• Dynamic factors: hopelessness, agitation, recent psychiatric hospitalization, recent loss or humiliation, command hallucinations, and acute alcohol or stimulant use.⁷
• Protective factors: connectedness, parental responsibility, religious belief, and engagement in treatment; protective factors do not negate active risk.⁷

Agitation and self-neglect

• Treat severe agitation with verbal de-escalation, environmental management, and as-needed medication (oral lorazepam or, when needed, IM lorazepam plus an antipsychotic).⁸⁵
• Address dehydration, malnutrition, and stopping essential medications in severe self-neglect; ECT is appropriate when oral intake is compromised.^23,49

Several long-standing debates in MDD remain unsettled and shape clinical decisions. The clinician's task is calibrating recommendations to the strength of evidence rather than to advocacy.⁵⁵

Antidepressant efficacy and effect size

• Pooled effect sizes of antidepressants over placebo are statistically significant but modest, with heterogeneity by severity; some analyses suggest larger benefit in severe depression and minimal benefit in mild depression.^55,87
• The Cipriani 2018 NMA confirmed superiority of all 21 studied agents over placebo, while acknowledging the modest absolute effect.³⁸

Serotonin hypothesis

• The 2023 umbrella review by Moncrieff et al. challenged the lay "chemical imbalance" framing and found no consistent evidence of low serotonin in depression; this reignited debate without overturning the clinical efficacy of serotonergic agents, whose mechanism is broader than acute synaptic 5-HT elevation.⁸⁸
• The clinical implication is communication: avoid telling patients depression is "a serotonin deficiency" while continuing to use SSRIs as evidence-based treatment.⁸⁸

Pediatric antidepressant safety

• The FDA boxed warning (2004, expanded 2007) for increased suicidal ideation and behavior in patients under 25 was followed by a documented decline in pediatric antidepressant prescribing and a coincident rise in pediatric suicide rates in some analyses; causality is debated.^60,89
• Risk-benefit calculations favor treatment of moderate-to-severe pediatric depression with close monitoring rather than withholding antidepressants.^64-65

Pharmacogenomic testing

• Commercial pharmacogenomic panels (CYP2D6, CYP2C19, etc.) are marketed for antidepressant selection, but RCTs and meta-analyses show, at best, small effect on remission compared with treatment as usual; major guidelines do not recommend routine use.³⁴

Esketamine and ketamine

• Esketamine intranasal is FDA-approved for TRD; concerns persist about dissociation, abuse potential, blood pressure effects, and durability of response beyond active treatment.⁴²
• IV racemic ketamine remains off-label in most jurisdictions, with rapid antidepressant and antisuicidal effects but limited durability and uncertain long-term safety with repeated dosing.^11,43

Psilocybin and MDMA-assisted therapy

• Psilocybin-assisted psychotherapy has shown promising acute antidepressant effects in phase 2 trials, including a 2021 randomized trial by Davis et al.; phase 3 trials are ongoing and the agent remains schedule I.⁹⁰
• FDA designated psilocybin a breakthrough therapy for TRD in 2018; efficacy claims should be calibrated to small samples, expectancy effects, and limited long-term safety data.⁹⁰

Maintenance duration

• The optimal duration of antidepressant maintenance remains debated; the ANTLER trial (2021, Lewis et al., NEJM) showed that discontinuation in primary care patients on long-term antidepressants nearly doubled relapse rates over a year compared with continuation.⁹¹
• Indefinite treatment is reasonable for highly recurrent course but should not be reflexive; periodic reassessment is appropriate.²

• DSM-5-TR requires at least five of nine symptoms during the same two-week period, with at least one being depressed mood or anhedonia.¹
• The DSM-IV bereavement exclusion was removed; an MDD diagnosis can be made within the first two months after a loss when full criteria are met.¹
• SSRIs are first-line for moderate-to-severe MDD; allow 4-6 weeks at therapeutic dose before declaring nonresponse.^2,36
• Citalopram has an FDA dose limit of 40 mg (20 mg in patients over 60) due to QTc prolongation.⁵⁹
• The FDA boxed warning for antidepressants applies to patients under 25 in the first weeks of treatment and mandates close monitoring.⁶⁰
• STAR*D demonstrated cumulative remission of approximately 67% across four sequential treatment steps, with diminishing returns at each step.⁴⁰
• ECT is the most effective acute treatment for severe, psychotic, catatonic, or treatment-resistant depression.^23,49
• Esketamine intranasal is FDA-approved for treatment-resistant depression in conjunction with an oral antidepressant under a REMS program.⁴²
• Sertraline is generally preferred during pregnancy and lactation among SSRIs based on transfer profile.^69-70
• Bupropion is contraindicated in seizure disorders and active eating disorders due to seizure risk.³⁷
• Venlafaxine has a dose-dependent effect on blood pressure and a notable discontinuation syndrome with abrupt cessation.^37,61
• The most replicated suicide risk factor is a prior suicide attempt; structured tools support but do not replace clinical judgment.^7,27
• TADS established that fluoxetine plus CBT outperforms either monotherapy in adolescent MDD.⁶⁵
• Recurrence risk rises from approximately 50% after one episode to 90% after three episodes.⁴
• Brexanolone and zuranolone are FDA-approved specifically for postpartum depression.^73-74

This article was prepared without industry sponsorship. The author reports no financial relationships with pharmaceutical or device manufacturers relevant to the content. Drug names are used for clinical accuracy and are not endorsements; brand names appear only when necessary to identify a specific FDA-approved product (e.g., esketamine [Spravato], brexanolone [Zulresso], zuranolone [Zurzuvae]).

This article is intended for clinician education and continuing medical education and is not a substitute for individual clinical judgment, local prescribing information, or current regulatory labeling. Readers should consult current FDA prescribing information and applicable regional regulatory guidance before clinical use.